Aldosterone Covid19

pubmed XX

33043967 2021. Serum ACE2, Angiotensin II, and Aldosterone Levels Are Unchanged in Patients With COVID-19.
32297520 2020. Can spironolactone be used to prevent COVID-19-induced acute respiratory distress syndrome in patients with hypertension?
32565254 2020. Activation of the renin-angiotensin-aldosterone system is associated with Acute Kidney Injury in COVID-19.
34204890 2021. Beneficial Effects of Mineralocorticoid Receptor Pathway Blockade against Endothelial Inflammation Induced by SARS-CoV-2 Spike Protein.
32513242 2020. Blocking mineralocorticoid receptor with spironolactone may have a wide range of therapeutic actions in severe COVID-19 disease.
34156969 2021. Electrolyte and acid-base imbalance in severe COVID-19.
32662949 2020. Modulation of the acute defence reaction by eplerenone prevents cardiac disease progression in viral myocarditis.
33587202 2021. COVID-19 mortality in the UK Biobank cohort: revisiting and evaluating risk factors.
33222412 2021. Association between renin-angiotensin-aldosterone system inhibitor use and COVID-19 hospitalization and death: a 1.4 million patient nationwide registry analysis.
32574273 2020. Symptomatic Protective Action of Glycyrrhizin (Licorice) in COVID-19 Infection?
33708781 2021. Effect of Spironolactone on COVID-19 in Patients With Underlying Liver Cirrhosis: A Nationwide Case-Control Study in South Korea.
32850920 2020. Spironolactone: An Anti-androgenic and Anti-hypertensive Drug That May Provide Protection Against the Novel Coronavirus (SARS-CoV-2) Induced Acute Respiratory Distress Syndrome (ARDS) in COVID-19.
33192504 2020. Coronavirus-19: Possible Therapeutic Implications of Spironolactone and Dry Extract of Glycyrrhiza glabra L. (Licorice).
34741250 2021. The elderly at risk: aldosterone as modulator of the immune response to SARS-CoV-2 infection.
33423528 2021. Antihypertensive Drugs and COVID-19 Risk: A Cohort Study of 2 Million Hypertensive Patients.
34884604 2021. Alternative RAS in Various Hypoxic Conditions: From Myocardial Infarction to COVID-19.
33249452 2021. New Horizons: Does Mineralocorticoid Receptor Activation by Cortisol Cause ATP Release and COVID-19 Complications?
32933039 2020. The Efficacy of the Mineralcorticoid Receptor Antagonist Canrenone in COVID-19 Patients.
32708205 2020. The Plasmatic Aldosterone and C-Reactive Protein Levels, and the Severity of Covid-19: The Dyhor-19 Study.
32749708 2021. Can aldosterone increase interleukin-6 levels in Covid-19 pneumonia?
32721806 2020. Spironolactone may provide protection from SARS-CoV-2: Targeting androgens, angiotensin converting enzyme 2 (ACE2), and renin-angiotensin-aldosterone system (RAAS).
32356628 2020. Renin-Angiotensin-Aldosterone System Inhibitors and Risk of Covid-19.
32356627 2020. Renin-Angiotensin-Aldosterone System Blockers and the Risk of Covid-19.
32356625 2020. Inhibitors of the Renin-Angiotensin-Aldosterone System and Covid-19.
32227760 2020. Renin-Angiotensin-Aldosterone System Inhibitors in Patients with Covid-19.
34915500 2021. Immunohistochemical and Transcriptional Analysis of SARS-CoV-2 Entry Factors and Renin-Angiotensin-Aldosterone System Components in Lethal COVID-19.
33477294 2021. COVID-19-The Potential Beneficial Therapeutic Effects of Spironolactone during SARS-CoV-2 Infection.
32659343 2020. Letter to the Editor - Circulating plasma levels of angiotensin II and aldosterone in patients with coronavirus disease 2019 (COVID-19): A preliminary report.
34593362 2021. The misunderstood link between SARS-CoV-2 and angiogenesis. A narrative review.
34193877 2021. Increased risk of acute kidney injury in coronavirus disease patients with renin-angiotensin-aldosterone-system blockade use: a systematic review and meta-analysis.
34880395 2021. The effect of renin-angiotensin-aldosterone system inhibitors on organ-specific ace2 expression in zebrafish and its implications for COVID-19.
32551456 2020. Use of Spironolactone in SARS-CoV-2 ARDS Patients.
34835015 2021. SARS-CoV-2 Spike Protein S1-Mediated Endothelial Injury and Pro-Inflammatory State Is Amplified by Dihydrotestosterone and Prevented by Mineralocorticoid Antagonism.
33539316 2021. Renin-angiotensin-aldosterone system peptide profiles in patients with COVID-19.
33278189 2020. Is Spironolactone the Preferred Renin-Angiotensin-Aldosterone Inhibitor for Protection Against COVID-19?
32966970 2020. Endocrine aspects of ACE2 regulation: RAAS, steroid hormones and SARS-CoV-2.
34862332 2021. A low aldosterone/renin ratio and high soluble ACE2 associate with COVID-19 severity.
33963054 2021. ILRUN Downregulates ACE2 Expression and Blocks Infection of Human Cells by SARS-CoV-2.
33487145 2020. [Results of Open-Label non-Randomized Comparative Clinical Trial: "BromhexIne and Spironolactone for Coronsmall a, CyrillicvirUs Infection requiring hospiTalization (BISCUIT)].

pubmed X

34805497 2021. Primary Adrenal Insufficiency After COVID-19 Infection.
33438198 2021. The swedish covid-19 intensive care cohort: Risk factors of ICU admission and ICU mortality.
33350096 2021. SARS-CoV-2 effects on the renin-angiotensin-aldosterone system, therapeutic implications.
34126079 2021. Renin-angiotensin-aldosterone system inhibitors and SARS-CoV-2 infection: an analysis from the veteran's affairs healthcare system.
32624189 2020. A Meta-analysis of the Relationship Between Renin-Angiotensin-Aldosterone System Inhibitors and COVID-19.
34265044 2021. Effects of Renin-Angiotensin-Aldosterone Inhibitors on Early Outcomes of Hypertensive COVID-19 Patients: A Randomized Triple-Blind Clinical Trial.
33048112 2021. Renin-Angiotensin-Aldosterone System Inhibitors and COVID-19 Infection or Hospitalization: A Cohort Study.
33404363 2021. Kinins and chymase: the forgotten components of the renin-angiotensin system and their implications in COVID-19 disease.
32412303 2020. Is the kidney a target of SARS-CoV-2?
32370986 2020. Renin-angiotensin-aldosterone system and COVID-19 infection.
33815782 2021. Covid-19, hypokalaemia and the renin-angiotensin-aldosterone system.
32815593 2020. Beta-Adrenergic Blockers as a Potential Treatment for COVID-19 Patients.
32993622 2020. Repurposing existing drugs for COVID-19: an endocrinology perspective.
32348783 2020. Hyperinflammation and derangement of renin-angiotensin-aldosterone system in COVID-19: A novel hypothesis for clinically suspected hypercoagulopathy and microvascular immunothrombosis.
33852652 2021. Renin-Angiotensin-Aldosterone System Inhibitors in COVID-19: A Review.
32332039 2020. Renin-angiotensin-aldosterone system inhibitors and COVID-19.
32601254 2020. Renin-angiotensin-aldosterone system inhibitors to treat COVID-19?
32544563 2020. COVID-19 cytokine storm: The anger of inflammation.
32852721 2020. Renin-Angiotensin-Aldosterone System Inhibitors and Risk of Death in Patients Hospitalised with COVID-19: A Retrospective Italian Cohort Study of 43,000 Patients.
32452762 2020. SARS-CoV-2 strategically mimics proteolytic activation of human ENaC.
34328182 2021. Roles of steroid receptors in the lung and COVID-19.
34031865 2021. Protecting older patients with cardiovascular diseases from COVID-19 complications using current medications.
32645153 2021. Inhibitors of the renin-angiotensin-aldosterone system and COVID-19 in critically ill elderly patients.
32671399 2020. Outcomes of renin-angiotensin-aldosterone system blockers in patients with COVID-19: a systematic review and meta-analysis.
32341103 2020. Understanding the renin-angiotensin-aldosterone-SARS-CoV axis: a comprehensive review.
33195477 2020. Small Resistance Artery Disease and ACE2 in Hypertension: A New Paradigm in the Context of COVID-19.
34512723 2021. ACE2 Netlas: In silico Functional Characterization and Drug-Gene Interactions of ACE2 Gene Network to Understand Its Potential Involvement in COVID-19 Susceptibility.
34194422 2021. Expression of ACE2, Soluble ACE2, Angiotensin I, Angiotensin II and Angiotensin-(1-7) Is Modulated in COVID-19 Patients.
33959029 2021. The Role of Renin-Angiotensin-Aldosterone System in the Heart and Lung: Focus on COVID-19.
33692701 2021. Controversial Roles of the Renin Angiotensin System and Its Modulators During the COVID-19 Pandemic.
33584343 2021. Pathogenesis of Multiple Organ Injury in COVID-19 and Potential Therapeutic Strategies.
33414726 2020. Physiology of Midkine and Its Potential Pathophysiological Role in COVID-19.
33876439 2021. Chronic use of renin-angiotensin-aldosterone system blockers and mortality in COVID-19: A multicenter prospective cohort and literature review.
32869673 2020. Renin-Angiotensin-Aldosterone System Inhibitors and Risks of Severe Acute Respiratory Syndrome Coronavirus 2 Infection: A Systematic Review and Meta-Analysis.
32458694 2020. Decreased Mortality of COVID-19 With Renin-Angiotensin-Aldosterone System Inhibitors Therapy in Patients With Hypertension: A Meta-Analysis.
32899833 2020. Cardiovascular Damage in COVID-19: Therapeutic Approaches Targeting the Renin-Angiotensin-Aldosterone System.
34860258 2021. Neue Aspekte der Glukokortikoidsubstitution bei Nebennierenrindeninsuffizienz.
34320843 2021. Renin-Angiotensin Aldosterone System Inhibitors in Primary Prevention and COVID-19.
33023356 2020. Antecedent Administration of Angiotensin-Converting Enzyme Inhibitors or Angiotensin II Receptor Antagonists and Survival After Hospitalization for COVID-19 Syndrome.
32839534 2021. Association between renin-angiotensin-aldosterone system inhibitor treatment, neutrophil-lymphocyte ratio, D-Dimer and clinical severity of COVID-19 in hospitalized patients: a multicenter, observational study.
33231299 2021. Effects of renin-angiotensin-aldosterone system inhibitors on disease severity and mortality in patients with COVID-19: A meta-analysis.
33038021 2021. Association of renin-angiotensin-aldosterone system inhibitors with mortality and testing positive of COVID-19: Meta-analysis.
32418199 2020. Angiotensin-converting enzyme 2 (ACE2), SARS-CoV-2 and the pathophysiology of coronavirus disease 2019 (COVID-19).
34349473 2021. Bidirectional Relationship between COVID-19 and Diabetes: Role of Renin-Angiotensin-Aldosterone System and Drugs Modulating It.
34853605 2021. Alamandine: Potential Protective Effects in SARS-CoV-2 Patients.
34285709 2021. Effects of the Na(+)/H(+) Ion Exchanger on Susceptibility to COVID-19 and the Course of the Disease.
33169633 2020. Angiotensin II, III, and IV may be important in the progression of COVID-19.
33787911 2021. Association Between Renin-Angiotensin-Aldosterone System Inhibitors and Clinical Outcomes in Patients With COVID-19: A Systematic Review and Meta-analysis.
34392451 2021. How SARS-CoV-2 might affect potassium balance via impairing epithelial sodium channels?
33893295 2021. COVID-19 pathophysiology may be driven by an imbalance in the renin-angiotensin-aldosterone system.
34371831 2021. Food Enrichment with Glycyrrhiza glabra Extract Suppresses ACE2 mRNA and Protein Expression in Rats-Possible Implications for COVID-19.
34642634 2021. Renin Angiotensin Aldosterone System Antagonism in 2019 Novel Coronavirus Acute Lung Injury.
33154144 2020. Renin-angiotensin-aldosterone system inhibitors and the risk of mortality in patients with hypertension hospitalised for COVID-19: systematic review and meta-analysis.
32658389 2020. The renin-angiotensin-aldosterone system: Role in pathogenesis and potential therapeutic target in COVID-19.
34673795 2021. Angiotensin II receptor blocker intake associates with reduced markers of inflammatory activation and decreased mortality in patients with cardiovascular comorbidities and COVID-19 disease.
33378401 2020. Safety, tolerability, and outcomes of losartan use in patients hospitalized with SARS-CoV-2 infection: A feasibility study.
34477316 2021. SGLT2-Inhibition reverts urinary peptide changes associated with severe COVID-19: An in-silico proof-of-principle of proteomics-based drug repurposing.
33398362 2021. Renin-Angiotensin-Aldosterone System (RAAS) Inhibitors and Coronavirus Disease 2019 (COVID-19).
32691370 2021. SARS-CoV-2 Entry Receptor ACE2 Is Expressed on Very Small CD45(-) Precursors of Hematopoietic and Endothelial Cells and in Response to Virus Spike Protein Activates the Nlrp3 Inflammasome.
32553503 2020. Drugs acting on renin angiotensin system and use in ill patients with COVID-19.
33124029 2020. Immunoinflammatory, Thrombohaemostatic, and Cardiovascular Mechanisms in COVID-19.
33422689 2021. Endothelial cells and SARS-CoV-2: An intimate relationship.
32992048 2020. RAAS inhibitors are not associated with mortality in COVID-19 patients: Findings from an observational multicenter study in Italy and a meta-analysis of 19 studies.
34581611 2021. The critical role of microvesicles in the modulation of renin-angiotensin-aldosterone system in endothelial homeostasis.
32926815 2020. 5 classes of antihypertensive drugs were not linked to positive COVID-19 test results or severe COVID-19.
32558905 2020. Renin-Angiotensin-Aldosterone Inhibitors and Susceptibility to and Severity of COVID-19.
32943474 2021. COVID-19 and the heart: what we have learnt so far.